Preclinical models for cell cycle-targeted therapies

Adv Exp Med Biol. 2006;587:139-47. doi: 10.1007/978-1-4020-5133-3_13.

Abstract

Deregulation of the cell cycle machinery is frequently associated to tumor development in most cell types. Many of these tumor-associated alterations result in the abnormal activation of cyclin-dependent protein kinases (Cdks) involved in the G1/S transition. Recent results from the genetic analysis of cyclins and Cdks in mouse models have raised some questions regarding the relevance of these molecules in cell cycle-targeted strategies for cancer therapy. The comprehensive evaluation of these biochemical and genetic data seems to be a necessary given the relevance of these and other new cell cycle kinases as targets for therapeutic approaches in cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Cycle / physiology
  • Cell Cycle Proteins / physiology*
  • Disease Models, Animal*
  • Humans
  • Mice*
  • Neoplasms / physiopathology*
  • Neoplasms / therapy*

Substances

  • Cell Cycle Proteins